



EUSTAR Abstracts at Systemic Sclerosis World Congress 2026

Oral Presentations

Thursday, March 5

13:45–14:45 | Trianti Hall

Session 1 – Lung

- **14:25–14:35: OC 01** – Contemporary treatment patterns and clinical determinants of therapy choices in systemic sclerosis-associated interstitial lung disease: insights from the EUSTAR database – Corrado Campochiaro et al (Italy)
- **14:35–14:45: OC 02** – Risk factors and trajectories of interstitial lung disease in patients with limited cutaneous systemic sclerosis in the EUSTAR cohort – Antonio Tonutti et al (Italy)

15:10–16:00 | Trianti Hall

Session 2 – Heart

- **15:30–15:40: OC 03** – Initial therapy in SSc-PAH improves outcomes across haemodynamic thresholds and risk stratification: insights from the EUSTAR database – Hilde Jenssen Bjørkekjær et al (Norway)

Friday, March 6

09:00–10:00 | Trianti Hall

Session 4 – Vascular

- **09:40–09:50: OC 10** – Association between vasoactive–vasodilating therapy and reduced detection of pulmonary arterial hypertension in systemic sclerosis: evidence from a EUSTAR study – Cosimo Bruni et al (Switzerland)

Saturday, March 7

08:30–09:20 | Trianti Hall

Parallel Session 10 – Oral Presentation (Clinical)

- **08:40–08:50: OC 24** – Real-world evidence: prevalence and clinical outcome of patients meeting the inclusion criteria of the phase 3 trial DAISY (Detecting Effectiveness of Anifrolumab in SSc) – a EUSTAR cohort study – Lesley Anne Bissell et al (UK)
- **09:00–09:10: OC 26** – Which anti-centromere antibody–positive systemic sclerosis patients are less likely to develop organ involvement? Insights from the EUSTAR cohort – Jelena Colic et al (Serbia)

09:30–10:30 | Trianti Hall

Parallel Session 12 – Oral Presentation (Clinical)

- **10:20–10:30: OC 39** – Machine learning–driven phenotyping in systemic sclerosis: CRP-defined inflammation and clinical clusters – an EUSTAR registry analysis – Cristiana Sieiro Santos et al (UK)
-

Poster Presentations

03. Pathogenesis – Immune dysregulation, including autoantibodies

- **P.041** – Demographic and clinical features of systemic sclerosis patients with anti-U1RNP antibodies: a European Scleroderma Trials and Research (EUSTAR) analysis – Madeleine Venables

05. Interstitial lung disease

- **P.117** – Vasodilation with prostanoids influences progression of systemic sclerosis-associated interstitial lung disease: a EUSTAR cohort study – Cosimo Bruni
- **P.120** – Outcomes of upfront combination vs monotherapy with rituximab or mycophenolate mofetil for systemic sclerosis interstitial lung disease (SSc-ILD): results from an EUSTAR cohort study – Devis Benfaremo

06. Pulmonary hypertension

- **P.129** – Macitentan for pulmonary arterial hypertension associated with systemic sclerosis: results from the European Scleroderma Trials and Research Group (EUSTAR) database – Maria-Grazia Lazzaroni

08. GI system

- **P.181** – Vascular disease burden predicts gastrointestinal manifestations in systemic sclerosis: longitudinal analysis from the EUSTAR cohort – Louis Bebear

10. Skin and localized scleroderma

- **P.208** – Rethinking skin assessment: analysis of individual Rodnan skin site scores in early diffuse systemic sclerosis using the EUSTAR cohort – Tania Santiago
- **P.209** – Enrichment criteria for skin progression in future trials: a preliminary analysis of skin progression in limited cutaneous systemic sclerosis and sine scleroderma patients using the EUSTAR cohort – Tania Santiago

18. Miscellaneous

- **P.357** – Risk factors for cancer in systemic sclerosis, impact on disease phenotype and prognosis, and exploration of machine learning algorithms for personalized screening strategies: an EUSTAR study – Antonio Tonutti
- **P.376** – Prevalence and incidence of skin telangiectasia and their association with clinical features: analysis of the European Scleroderma Trials and Research (EUSTAR) cohort – Silvia Bellando-Randone
- **P.377** – Increased frequency of anti-RNA polymerase III antibodies in patients with systemic sclerosis and silicone breast implants: a multicentre study from the international EUSTAR cohort – Maria Grazia Lazzaroni
- **P.400** – The national landscape of systemic sclerosis in Egypt: a comprehensive EUSTAR database study – Rahma Elziaty